Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian M Thompson

Showing results (311-320 of 484) with videos related to

Pageof 49
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White menKathleen C Torkko, Adrie van Bokhoven, Phoung Mai, et al.
Cancer Causes & Control : CCC|November 22, 2015
Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention TrialJeannette M Schenk, Cathee Till, Ann W Hsing, et al.
Oncotarget|October 27, 2016
TGF-β signal rewiring sustains epithelial-mesenchymal transition of circulating tumor cells in prostate cancer xenograft hostsGuangcun Huang, Pawel A Osmulski, Hakim Bouamar, et al.
The Journal of Urology|February 13, 2014
Statin drug use is not associated with prostate cancer risk in men who are regularly screenedElizabeth A Platz, Catherine M Tangen, Phyllis J Goodman, et al.
The Prostate|June 22, 2016
Peripheral Zone Inflammation Is Not Strongly Associated With Lower Urinary Tract Symptom Incidence and Progression in the Placebo Arm of the Prostate Cancer Prevention Trial Ibrahim Kulac, Berrak Gumuskaya, Charles G Drake, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 26, 2016
Colorectal Adenomas in Participants of the SELECT Randomized Trial of Selenium and Vitamin E for Prostate Cancer PreventionPeter Lance, David S Alberts, Patricia A Thompson, et al.
Urology|March 26, 2014
Drug and device development for localized prostate cancer: report of a Food and Drug Administration/American Urological Association public workshopJonathan P Jarow, Ian M Thompson, Paul G Kluetz, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 1, 2015
Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention TrialSarah H Nash, Jeannette M Schenk, Alan R Kristal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2013
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance StudyDaniel W Lin, Lisa F Newcomb, Elissa C Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2008
Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapyCarol M Moinpour, Katherine A Hayden, Joseph M Unger, et al.
Pageof 49

Showing results (311-320 of 484) with videos related to

Sort By:
Pageof 49
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White menKathleen C Torkko, Adrie van Bokhoven, Phoung Mai, et al.
Cancer Causes & Control : CCC|November 22, 2015
Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention TrialJeannette M Schenk, Cathee Till, Ann W Hsing, et al.
Oncotarget|October 27, 2016
TGF-β signal rewiring sustains epithelial-mesenchymal transition of circulating tumor cells in prostate cancer xenograft hostsGuangcun Huang, Pawel A Osmulski, Hakim Bouamar, et al.
The Journal of Urology|February 13, 2014
Statin drug use is not associated with prostate cancer risk in men who are regularly screenedElizabeth A Platz, Catherine M Tangen, Phyllis J Goodman, et al.
The Prostate|June 22, 2016
Peripheral Zone Inflammation Is Not Strongly Associated With Lower Urinary Tract Symptom Incidence and Progression in the Placebo Arm of the Prostate Cancer Prevention Trial Ibrahim Kulac, Berrak Gumuskaya, Charles G Drake, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 26, 2016
Colorectal Adenomas in Participants of the SELECT Randomized Trial of Selenium and Vitamin E for Prostate Cancer PreventionPeter Lance, David S Alberts, Patricia A Thompson, et al.
Urology|March 26, 2014
Drug and device development for localized prostate cancer: report of a Food and Drug Administration/American Urological Association public workshopJonathan P Jarow, Ian M Thompson, Paul G Kluetz, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 1, 2015
Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention TrialSarah H Nash, Jeannette M Schenk, Alan R Kristal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2013
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance StudyDaniel W Lin, Lisa F Newcomb, Elissa C Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2008
Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapyCarol M Moinpour, Katherine A Hayden, Joseph M Unger, et al.
Pageof 49